Frequently asked questions

We accept Interac e-Transfer only.

Everything you need to send it — the amount, the address and your order number — is shown on screen the moment you place the order and repeated in your confirmation email. Your bank will not ask for a security question — the transfer deposits to us automatically the moment you send it. We hold your order and its stock for 24 hours while the transfer arrives, and dispatch within 48 business hours of it clearing. If your bank caps daily transfers, send two with the same order number in the message and we will match them. All prices are in Canadian dollars, and because shipping is free Canada-wide on every order with no minimum, the listed price is the delivered price before tax.

Yes — and the main reason is that there is no card checkout to compromise.

Interac e-Transfer is the only payment method, so no card number, no PayPal login and no payment credential of any kind is ever typed into this site or stored by us. There is nothing of that sort here to lose. The site is served over HTTPS throughout, your order and address travel encrypted, and the transfer itself is sent from inside your own banking app, which we never see into. We do not sell, rent or share customer data with third parties. If anything about an order or a transfer looks wrong, email info@thepeptide.ca with your order number and we will trace it.

Always — every order ships in plain, unbranded outer packaging with no product names, no logos and nothing on the outside identifying the contents.

Vials are individually wrapped inside temperature-stable, tamper-evident material with padding, so the parcel is protected and does not advertise itself. Payment is by Interac e-Transfer, so there is no card statement to read in the first place: your bank records a transfer, not a purchase. Dispatch is within 48 hours on business days from British Columbia, and your tracking number is emailed at that point. Discretion is standard on every order — there is nothing to select and no surcharge.

Yes — two kinds.

Join our email list and you will get a 10% off code for your first order, plus restock alerts and new-lot results as they are published. Separately, an automatic volume discount applies at checkout with no code needed: 10% off at three or more items, 15% at five or more, and 20% at ten or more on everything in your order. Shipping is already free Canada-wide on every order with no minimum, so a discount comes off the product price rather than a shipping charge. Note that one larger vial is often better value per milligram than several small ones.

No — because we ship domestically from within Canada, orders never cross the border, so there are no customs inspections, import duties or brokerage fees that overseas shipments often trigger.

Shipping is free Canada-wide with no minimum, dispatched within 48 hours and tracked. Applicable Canadian sales tax is calculated at checkout according to your province, and it is the only amount added to the listed price.

We ship across Canada only — to every province and territory, including the North.

We do not ship internationally and we do not ship to the United States, which is deliberate: a domestic parcel never crosses a border, so there are no CBSA inspections, no import duties and no brokerage fees. Every order leaves from British Columbia. Shipping is free with no minimum order value, every parcel is tracked, and orders are dispatched within 48 hours on business days with typical delivery in 2–8 business days. Remote and northern postal codes sit at the longer end of that window.

Shipping is free on every order, Canada-wide, with no minimum order value — the listed price is the delivered price before tax.

There is no threshold to reach, no weight surcharge, no remote-area surcharge, and no charge for tracking, which is included on every parcel. That applies equally to a single $44.99 Semaglutide 5mg vial and to a $180 Retatrutide 30mg vial. Orders are dispatched within 48 hours on business days from British Columbia and typically arrive in 2–8 business days to major centres, and up to 14 for remote and northern addresses. Because we ship domestically, there are also no duties, customs fees or brokerage charges added on delivery.

Orders are dispatched within 48 hours on business days from British Columbia and typically arrive within 2–8 business days to major centres, and up to 14 for remote and northern addresses.

The 48-hour figure is our processing commitment, Monday to Friday; the 2–8 day range is transit, and it is the same commitment to every province and territory rather than a per-city promise. Canada Post's own published standards put most major centres one to two days from a Vancouver origin on Priority service, with Halifax and Québec City further out — but those are the carrier's figures for a different service level, not ours. A tracking number is emailed the moment the parcel is dispatched.

Yes — every parcel is tracked, with no minimum order and no extra charge, and the tracking number is emailed to you the moment your order is dispatched.

Dispatch happens within 48 hours on business days from British Columbia, so if no tracking email has arrived after two business days, check your spam folder and then email info@thepeptide.ca with your order number. Carrier scans can lag a parcel's actual movement by several hours, particularly over a weekend, so a quiet day mid-transit is normal. Typical transit is 2–8 business days to major centres and up to 14 for remote and northern addresses; if a parcel stops updating for more than five business days, contact us and we will open a trace.

Discreetly and securely — plain, unbranded outer packaging, with each vial individually wrapped in temperature-stable, tamper-evident material and padded against impact.

Lyophilized peptide needs no cold chain for a domestic transit window, so parcels travel at ambient temperature; the freeze-dried form is stable for the few days it spends with the carrier. The lot number is printed on every vial and is what ties it to its published lot figures, so do not remove or write over the label. Nothing on the outside of the parcel identifies the contents. On arrival, move sealed vials into cold storage rather than leaving them on a bench.

We publish a record, not a promise.

Most single-peptide lots we have published have assayed above 99%, and each lot's figures go up before the lot goes on sale, so you can check them rather than take them on trust. Several recent lots landed comfortably above that line: Retatrutide 10mg lot reta10-0626-03 at 99.8%, Tirzepatide lot TIRZ10-0626-01 at 99.65%, and the Retatrutide 20mg and 30mg lots at 99.643% and 99.751%. Not every lot does: our own Testides confirmation on an earlier Tesamorelin 10mg lot, CS-te10-0616, came back at 95.19%, and that figure is still published on the Lab Results page and the product page exactly like the others even though the lot has sold through. Its replacement, lot tesa10-0626-03, assayed at 99.7% — which is the point of publishing per lot rather than per product. Of the lots currently on sale, Semaglutide 10mg at 98.92% is the only single peptide below 99%. A guarantee that quietly drops its worst result is not a record. Pre-blended products such as the Wolverine Blend are verified for the identity and amount of each component instead, because a two-peptide vial has no single meaningful purity number. Whatever a lot assays at, that is the figure we publish.

Email info@thepeptide.ca with your order number and photographs of any damage, and we will replace the order or refund it in full.

For a parcel that stops tracking we open a trace with the carrier rather than making you wait out the full delivery window first, and if it cannot be found we replace it or refund it. Those two cases — a parcel that never arrives, and one that arrives damaged — are the whole of our refund policy. We cannot accept returns or exchanges on delivered product, opened or sealed, for chain-of-custody reasons rather than policy convenience: a vial we cannot vouch for is a vial we cannot sell to anyone else. We reply in 2–4 hours during business hours, Mon–Fri 9am–6pm PT.

Email info@thepeptide.ca or use our contact form, and we reply in 2–4 hours during business hours, Mon–Fri 9am–6pm PT.

Include your order number if the question is about an existing order, or the lot number printed on the vial if it is about a certificate — that lets us answer in one reply instead of three. We can help with orders, tracking, lot certificates, net peptide content, bulk quotes and restock timing. We cannot answer questions about human use: we publish no such guidance and do not provide it on request, for any compound, to anyone. Support is handled from New Westminster, British Columbia.

Yes — by Janoshik Analytical, a widely-recognised independent testing lab, which assays every batch before it ships.

We then commission our own confirmatory testing on that same batch — HPLC for purity, mass spectrometry for identity — from Testides in Toronto, from VialTests, or from SideChain Analytics in Mississauga where the method calls for it, and publish each lot's figures here as they clear. Thirteen of our nineteen published lots have completed both steps so far; on the remaining six our own confirmation is still in progress and the Janoshik result stands in the meantime, labelled as such. No batch is sold on our word alone.

A Certificate of Analysis is the laboratory document for one specific production lot, and it is the only evidence that the contents of a vial match its label.

A complete certificate names the compound and confirms its identity by mass spectrometry, states purity as a percentage measured by HPLC-UV, gives the net peptide content in milligrams, and carries the lot number, the test date and the issuing laboratory. Ours are issued by Janoshik Analytical, by Testides in Toronto, by SideChain Analytics in Mississauga and by VialTests. We do not host those documents. What we publish, per lot and open to anyone with no login, are the figures off them — for example lot reta10-0626-03 at 99.8% purity, reported 30 October 2026. Thirteen lots additionally carry a report number from the laboratory that ran our own confirmation: seven from Testides, which you can check yourself at testides.com/verify, five — Retatrutide 10mg, TB-500 10mg, Tesamorelin 10mg, the GLOW Blend and the Tesamorelin + Ipamorelin Blend — from VialTests at vialtests.com/verify, and one — MOTS-C 10mg — from SideChain Analytics, referenced on that lot's entry. A generic certificate carrying no lot number is not a certificate.

Read the lot number printed on the vial, then look that lot up on our Lab Results page — every lot's published figures are filed under its lot number.

Lot numbers follow a readable format: reta10-0626-03 for the Retatrutide 10mg lot, TIRZ10-0626-01 for Tirzepatide, CS-re20-0710 and CS-re30-0718 for the two larger Retatrutide vials. The entry shows purity by HPLC-UV at 214 nm, identity confirmed by mass spectrometry, and the net peptide content in milligrams. If the number on your vial does not match a published lot, email info@thepeptide.ca.

Check the lot number on the vial against its published figures — that is the only reliable test available to a buyer.

Every lot is verified before release: HPLC-UV measures purity, mass spectrometry confirms the molecule's identity, and the net peptide content is weighed and reported in milligrams, so a short-filled vial shows up as clearly as a mislabelled one. Each lot's numbers are published on our Lab Results page under its own lot number with the issuing laboratory named — Janoshik Analytical, Testides in Toronto, VialTests or SideChain Analytics in Mississauga — open to anyone, no login. A seller who publishes only a generic certificate with no lot number has given you nothing to check.

Twice, by two different laboratories, drawn from four we use.

First, each batch is assayed by Janoshik Analytical — an independent, widely-trusted testing lab — to confirm identity and purity before release. Then we commission our own independent HPLC and mass-spec confirmation on the same batch, and which laboratory runs it depends on the method: Testides in Toronto for most lots, SideChain Analytics in Mississauga where a mass-spectrometry method or an endotoxin assay is called for. Those figures go on our Lab Results page for anyone to read, no login. Thirteen of our nineteen published lots have cleared both steps so far — eight confirmed by Testides, each carrying a report number you can check yourself at testides.com/verify; three — Retatrutide 10mg, TB-500 10mg and the GLOW Blend — confirmed by VialTests, checkable the same way at vialtests.com/verify; and one, MOTS-C 10mg, confirmed by SideChain Analytics, which also returned a separate bacterial endotoxin certificate. The remaining six show their Janoshik figures while our confirmation is in progress, so you always see current lab data.

HPLC measures purity and mass spectrometry confirms identity — they answer two different questions, and a complete certificate needs both.

High-performance liquid chromatography separates the target peptide from truncated sequences, deletion products and process impurities and reports the target as a percentage of total peak area; ours are run as HPLC-UV with detection at 214 nm, the absorbance wavelength of the peptide bond, which is why it is the standard for peptide assay. Mass spectrometry (LC-MS/MS) measures molecular mass to confirm the correct molecule is present — a sample can be 99% pure and be 99% of the wrong peptide, which a purity figure alone would never reveal.

Endotoxin testing measures bacterial lipopolysaccharide — a heat-stable cell-wall fragment shed by Gram-negative bacteria that can trigger inflammatory responses in cell culture and animal models at picogram levels, and can therefore confound a result no matter how pure the peptide is.

The standard method is the Limulus Amebocyte Lysate (LAL) assay, most often run in the kinetic chromogenic format harmonised as USP <85>, with results reported in endotoxin units per milligram. It answers a different question from HPLC-UV purity or mass-spectrometry identity: not "is this the right molecule, and how pure", but "is it contaminated". The figures we publish cover purity and identity; endotoxin is a separate assay a laboratory may commission for endotoxin-sensitive work.

Two independent tests on every batch remove single-source bias.

Every batch is assayed by Janoshik Analytical before release, and we then commission our own confirmation on the same batch by HPLC-UV for purity and LC-MS/MS for identity — from Testides in Toronto for most lots, from VialTests, and from SideChain Analytics in Mississauga where a mass-spectrometry method or an endotoxin assay is called for. Two laboratories agreeing is far stronger evidence that a vial is correctly identified and at its stated purity than one laboratory's word, and a disagreement would surface before the lot went on sale rather than after. We publish each lot's figures under its lot number as they clear — purity, measured content, method, lab and report date — open to anyone, no login. Thirteen of our nineteen published lots have completed both steps so far. We do not list them here, because a list like that goes stale the week after it is written — each lot is marked on the Lab Results page with the laboratory that confirmed it and its report number. On the remaining six our confirmation is still in progress, the Janoshik result stands in the meantime, and it is labelled as such.

A batch (lot) number is a unique identifier tying one specific vial to one production run and to the certificates issued for it.

It is what makes verification possible at all: without it, a purity figure is a marketing claim about material in general rather than evidence about the vial in your hand — the standard defence against short-filled or mislabelled product. Our lot numbers are printed on the vial and follow a readable format, such as reta10-0626-03 for the Retatrutide 10mg lot or CS-re30-0718 for the 30mg. Each is published on the Lab Results page with its own purity figure, net content in milligrams, method, laboratory and test date.

Check four things: the peptide name and molecular mass (identity, confirmed by mass spectrometry), the purity percentage (from HPLC-UV), the net peptide content in milligrams, and the lot number, test date and issuing lab.

Match the lot number to the vial you received before reading anything else — a certificate for a different lot tells you nothing about your vial. On our Retatrutide 10mg certificate, for instance, those fields read: retatrutide, 99.8% by HPLC-MS/MS, 13.41 mg net content, lot reta10-0626-03, reported 30 October 2026 by VialTests.

A blind test is one where the laboratory is not told what the sample is supposed to be, so it must identify the compound from its own analysis rather than confirm a label.

That removes confirmation bias: an ordinary assay answers "does this match the stated compound?", while a blind assay answers the harder question, "what is this?". Our Retatrutide 20mg and 30mg lots were run this way — Janoshik Analytical was given three candidate compounds, was not told which the sample was, and identified retatrutide from the data alone. Those results are published as lot CS-re20-0710 at 99.643% (Janoshik ref #207689) and lot CS-re30-0718 at 99.751% (ref #210575).

Purity is a percentage and net peptide content is a mass — purity is the share of the material that is the target peptide rather than truncated sequences or process impurities, while net content is the actual milligrams of peptide in the vial.

A vial can be 99.7% pure and still be short-filled, which is why the two figures have to be read together and why a certificate reporting only one of them is incomplete. Our certificates report both: the Retatrutide 10mg lot reta10-0626-03 assayed at 99.8% by HPLC-MS/MS with 13.41 mg against a 10 mg label, and the Tirzepatide lot TIRZ10-0626-01 at 99.65% with 10.34 mg.

Match the lot number on the vial to the published figures, then confirm those figures with the issuing laboratory rather than trusting a seller's own page.

Testides has no per-report link either: you enter the report number by hand into the lookup form at testides.com/verify — our Tirzepatide 10mg lot carries report reference ARUA-TIRZ-10-061826 — VialTests takes its report number at vialtests.com/verify, where our Retatrutide 10mg lot reta10-0626-03 is report VT-2026-001827-02, and Janoshik reports carry a reference number, such as #207689 for our Retatrutide 20mg lot, that can be checked with the lab directly. Then read the four fields that matter: identity confirmed by mass spectrometry, purity by HPLC — at 214 nm where the method is HPLC-UV, or by HPLC-MS/MS where that is what was run — net peptide content in milligrams, and the report date. If a lot number on a vial has no matching published entry, that is your answer.

Every batch is assayed by Janoshik Analytical first, then sent for our own independent re-testing — at Testides in Toronto, at VialTests, or at SideChain Analytics in Mississauga where the method calls for it — and those results are added as they are completed, so a batch may temporarily display only the Janoshik COA while our confirmation is pending.

Six of our nineteen published lots are at that stage right now; the other thirteen have cleared. The Janoshik result already verifies purity and identity; the second laboratory is an added, independent confirmation. All results post per batch.

Keep lyophilized (dry) vials sealed in their original packaging, protected from light and moisture.

For long-term storage keep them in a freezer at −20 °C or below, where they remain stable well beyond a year; a fridge at 2–8 °C is fine for short-term storage. Let a vial reach room temperature before opening it, so condensation does not form on the cold powder. Choose one location and leave the vial there rather than moving it between fridge and freezer.

No — room temperature is a transit condition, not a storage condition.

A sealed lyophilized vial tolerates the few days it spends with a carrier at ambient temperature without measurable loss, which is why domestic parcels need no cold chain, but that tolerance is not the same as shelf stability over months. For storage, a freezer at −20 °C or below is the long-term condition and keeps sealed vials stable well beyond a year; a fridge at 2–8 °C is the short-term condition, and it is what the specification table on every product page lists. Move vials into cold storage on arrival, still sealed and still in their original carton.

Yes — repeated warming and re-cooling is one of the few things that meaningfully shortens the shelf life of a sealed lyophilized vial, so pick one storage temperature and leave the vial at it.

Every cycle between −20 °C and ambient invites humid air to condense inside the packaging, and moisture is the principal enemy of freeze-dried peptide. A vial left undisturbed in a freezer at −20 °C or below will outlast an identical vial shuttled in and out of a fridge door, which is the warmest and most thermally unstable part of any refrigerator. If material is needed in stages, order the vial count the study needs rather than cycling one vial repeatedly.

Because a vial taken straight from a −20 °C freezer is far colder than the surrounding air, and breaking the seal lets humid room air condense as water directly onto the freeze-dried powder.

Lyophilized peptide is hygroscopic — it readily takes up atmospheric water — and absorbed moisture is what degrades it, which is why every specification sheet we publish pairs a storage temperature with "protect from light and moisture". Let the sealed vial stand until it has equilibrated to room temperature before the seal is broken; for a small vial that is a matter of minutes, not hours. This is standard laboratory handling for any lyophilized reference material, not a peptide-specific quirk.

Keep each vial sealed inside its original carton until it reaches the laboratory: the carton is the light barrier and the intact crimp seal is the moisture barrier.

Our published specification tables list "protect from light" for every compound, and it matters most for the light-sensitive ones such as GHK-Cu, whose blue colour comes from bound copper(II). Store the carton in a dark, dry part of the freezer or fridge rather than on a door shelf, and avoid a frost-free compartment that runs a periodic defrost cycle. Do not decant, relabel or repackage a sealed vial — the lot number printed on it is what ties it to its published figures.

A sealed lyophilized vial kept at −20 °C or below is generally stable for around 24 months, and frequently well beyond, provided it stays sealed and protected from light and moisture.

The freeze-dried form is what buys that shelf life: with the water removed, the hydrolysis and aggregation pathways that normally limit peptide stability largely stop. Short-term refrigeration at 2–8 °C is fine for material that will be used soon. What actually shortens shelf life is handling rather than elapsed time — repeated temperature cycling, a compromised seal, or storage somewhere humid. Keep the vial in its original carton in one stable location.

No — lyophilized peptides do not require a cold chain in transit, and we do not ship with ice packs.

Freeze-dried material is stable at ambient temperature for far longer than a parcel spends with the carrier, so a 2–8 business-day domestic transit causes no measurable degradation. Ice packs would add cost and, once thawed, introduce the one thing that genuinely damages lyophilized peptide: moisture. Parcels travel in temperature-stable, tamper-evident packaging that protects against impact and light. The cold-storage requirement begins on arrival — move sealed vials into a fridge at 2–8 °C or a freezer at −20 °C or below.

Bacteriostatic water is sterile water containing 0.9% benzyl alcohol (CAS 100-51-6) as a bacteriostatic preservative, which inhibits microbial growth.

We stock it purely as a general laboratory supply in two sizes — a 3 mL vial at $12.99 and a 10 mL vial at $22. It is not a peptide product, so it carries no HPLC purity assay; the relevant specifications are sterility and preservative concentration, not a purity percentage. It is supplied for laboratory use only. We publish no human-use guidance for it or for any other item in the catalogue, and we do not provide such guidance on request.

Research peptides are short chains of amino acids — typically fewer than 50 residues — supplied as reference materials for in-vitro and preclinical laboratory work.

They sit between single amino acids and full proteins in size: BPC-157 is a pentadecapeptide of 15 residues, MOTS-C is 16, Ipamorelin is a pentapeptide of 5, and tirzepatide runs to 39. Each is defined by an exact amino-acid sequence and a CAS registry number, which is what a laboratory confirms by mass spectrometry. Everything we supply is sold strictly as laboratory research material — not for human or veterinary use.

BPC-157 is a synthetic pentadecapeptide of 15 amino acids (CAS 137525-51-0) derived from a partial sequence of a protective protein found in human gastric juice.

Preclinical models study it for tissue-repair signalling, cytoprotection, angiogenesis through the VEGF pathway, and modulation of nitric-oxide signalling — Sikiric et al. (Journal of Physiology-Paris, 1999, PMID 10574216) established the cytoprotective profile, and Seiwerth et al. (Current Pharmaceutical Design, 2018, PMID 29589535) is the standard review. The evidence is almost entirely animal and in-vitro, with no large published human trials. Our 10mg lot is verified at 99.64% purity by HPLC with mass-spectrometry identity confirmation through Testides in Toronto.

TB-500 is a synthetic peptide corresponding to the active actin-binding region of thymosin beta-4, a 43-amino-acid protein present in most mammalian cells and one of the most abundant proteins in wound fluid.

Research models investigate it for actin sequestration, cell migration, angiogenesis and tissue repair — a mechanism that runs parallel to, rather than overlapping with, BPC-157's nitric-oxide and VEGF signalling, which is why the two are so often studied as a pair. The evidence base is preclinical: animal and in-vitro work, with no large published human trials. Supplied strictly as laboratory research material.

GHK-Cu is a copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with copper(II) — with CAS number 89030-95-5, molecular formula C14H21CuN6O4 and a molecular weight of 400.91 g/mol.

It occurs naturally in human plasma and its concentration declines markedly with age, which is why the literature frames it as a repair and remodelling signal rather than a growth factor. In-vitro and topical models study it for collagen and elastin synthesis, extracellular-matrix remodelling, antioxidant and anti-inflammatory pathways, and copper transport; Pickart and Margolina (International Journal of Molecular Sciences, 2018, PMID 29986520) is the standard review. Our 50mg vial is a blue lyophilized powder — the colour is the bound copper(II) and is expected.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA — CAS 1627580-64-6, sequence MRWQEMGYIFYPRKLR, molecular weight 2,174.62 g/mol.

Unlike the incretin class it acts from inside the mitochondrion rather than at a cell-surface receptor: under metabolic stress it translocates to the nucleus and regulates AMPK-dependent gene expression governing glucose utilisation, insulin sensitivity and fatty-acid metabolism. Lee et al. (Cell Metabolism, 2015, PMID 25738459) is the founding characterisation and Reynolds et al. (Nature Communications, 2021, PMID 33397889) covers exercise-induced expression. Our current 10mg lot assayed at 99.025% by HPLC-UV at Janoshik Analytical.

The Wolverine Blend is a single 10mg vial containing BPC-157 and TB-500 together, 5mg of each, priced at $95.

The two are studied as a pair in preclinical tissue-repair models because their mechanisms are complementary rather than redundant: BPC-157 acts through nitric-oxide and VEGF-linked angiogenic signalling, while TB-500 works through actin binding and cell migration. Because it is a blend, its certificate verifies the identity and the amount of each component rather than reporting one purity percentage — a two-peptide vial has no single meaningful figure. Evidence for both components is preclinical.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that acts at the GHRH receptor on the pituitary to prompt growth hormone release in research models.

It exists in two forms that are frequently confused: the short-acting version, often labelled modified GRF(1-29), and the DAC version, which carries a Drug Affinity Complex that binds serum albumin and extends its half-life from minutes to days. That distinction matters when reading a certificate, because the two are different molecules with different masses. We supply it only within the pre-blended CJC-1295 + Ipamorelin 10mg vial (5mg + 5mg) at $79.

Ipamorelin (NNC 26-0161, CAS 170851-70-4) is a selective growth hormone secretagogue: a pentapeptide agonist at the ghrelin receptor GHS-R1a, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight 711.85 g/mol.

It is described as the first selective GH secretagogue because in Raun et al. (European Journal of Endocrinology, 1998;139(5):552-561) it released growth hormone with potency comparable to GHRP-6 but without meaningfully raising ACTH, cortisol or prolactin. Its clinical programme for postoperative ileus was discontinued for lack of efficacy on the primary endpoint, and it has never been an approved medicine. Supplied as a 10mg lyophilized research vial at $74.99.

Retatrutide (LY3437943, CAS 2381089-83-2) is an investigational triple receptor agonist that activates the GLP-1, GIP and glucagon receptors, and it is not approved by Health Canada or the FDA.

Eli Lilly's Phase 3 TRIUMPH programme is ongoing, with TRIUMPH-1 topline data reported in May 2026, following its published Phase 2 results. Its molecular formula is C221H342N46O68 at 4,731.42 g/mol. We supply it strictly as laboratory research material in three vial sizes — 10mg at $90, 20mg at $140 and 30mg at $180 — each with its own published lot figures; the 10mg lot reta10-0626-03 was verified at 99.8% purity by HPLC-MS/MS.

Yes — Tesamorelin 10mg is in stock at $99.99.

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44), stabilised by a trans-3-hexenoyl group at the N-terminus that resists cleavage by DPP-4, giving it a longer plasma life than the native hormone. That places it in the same GHRH-analogue family as CJC-1295, and makes it a useful comparator against the secretagogue we also stock, Ipamorelin (CAS 170851-70-4), which reaches the growth hormone axis through the ghrelin receptor instead. The lot in stock is tesa10-0626-03, assayed for us by VialTests at 99.7% chromatographic purity by HPLC-MS/MS with 9.68 mg of net peptide against the 10 mg label, identity confirmed against a reference standard, under report VT-2026-001827-S03 reported 5 November 2026. It replaced lot CS-te10-0616, which read 99.174% at Janoshik (report #198440) and 95.19% with 9.94 mg on our own Testides report ARUA-TESA-10-092026 — 16.3% apart on content. All of those figures stay published, the low one included. It is supplied strictly as laboratory research material.

Yes — Semax 10mg is in stock at $64.99.

Semax is a synthetic peptide analogue of the ACTH(4-7) fragment carrying a Pro-Gly-Pro tail at the C-terminus, a modification that markedly slows enzymatic breakdown compared with the parent fragment. Developed in Russia, most of its literature concerns BDNF expression and neurotrophic signalling in preclinical models, which makes it the only neuropeptide in our range and the reason it sits in its own Cognitive collection. Our lot CS-sem10-0625 assayed at 99.138% by Janoshik Analytical (report #200391), with Testides confirmation still pending. It has no Health Canada or FDA approval and is supplied strictly as laboratory research material.

They differ by how many receptors each one activates.

Semaglutide is a single GLP-1 receptor agonist with a terminal half-life of about seven days; Tirzepatide is a 39-amino-acid dual agonist at the GIP and GLP-1 receptors with a half-life near five days; Retatrutide adds a third target, the glucagon receptor, making it a triple agonist and the newest of the three. Their evidence status differs just as much: semaglutide and tirzepatide have completed Phase 3 programmes and are approved medicines, while retatrutide remains investigational with Phase 3 TRIUMPH ongoing. We stock all three as lyophilized research vials with published lot figures.

Among the compounds we carry, the incretin peptides have by far the strongest human evidence.

Semaglutide (the STEP and SUSTAIN programmes; Wilding et al., New England Journal of Medicine, 2021, PMID 33567185) and tirzepatide (SURPASS-2, PMID 34170647; SURMOUNT-1, PMID 35658024) both have completed Phase 3 trials published in the NEJM, and retatrutide has published Phase 2 data with the Phase 3 TRIUMPH programme ongoing. Repair and signalling peptides sit far lower: BPC-157, TB-500, GHK-Cu and MOTS-C rest almost entirely on preclinical animal and in-vitro work, with no large human trials. We rank them honestly rather than flattening the difference.

Semaglutide has a terminal half-life of approximately seven days (around 165 hours), the longest of any compound in our catalogue.

That duration comes from a C18 fatty-diacid side chain that binds circulating albumin and slows renal clearance, combined with amino-acid substitutions that resist DPP-4 degradation. It is the reason the registrational trials were built around a once-weekly schedule — the STEP programme for weight endpoints and SUSTAIN for glycaemic endpoints, with Wilding et al. (New England Journal of Medicine, 2021, PMID 33567185) the most cited among them. We stock it as 5mg ($44.99) and 10mg ($69.99) lyophilized research vials, verified by HPLC through Janoshik Analytical at 99.247% (5mg, ref #101805) and 99.664% (10mg, ref #171488), with Testides confirmation still pending.

Tirzepatide is a single 39-amino-acid peptide that activates both the GIP and the GLP-1 receptor, and its terminal half-life is roughly five days (about 120 hours).

Engaging two incretin receptors produced larger effects on trial endpoints than GLP-1 activation alone: SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) set it head-to-head against semaglutide on glycaemic endpoints, and SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) covered weight endpoints. Both trial programmes used a once-weekly schedule. Our current lot, TIRZ10-0626-01, was verified at 99.65% purity by HPLC-UV at 214 nm by Testides in Toronto and assayed at 10.34 mg.

The difference is one receptor: tirzepatide is a dual agonist at GIP and GLP-1, while retatrutide adds a third target, the glucagon receptor, making it a triple agonist.

Their development status differs just as sharply — tirzepatide has completed Phase 3 and is an approved medicine, whereas retatrutide (LY3437943, CAS 2381089-83-2) remains investigational, with Eli Lilly's Phase 3 TRIUMPH programme ongoing and TRIUMPH-1 topline data reported in May 2026. In their published trials, participants in both programmes received the compound on a once-weekly schedule. We supply both strictly as research material: Tirzepatide 10mg at $74.99, Retatrutide at $90, $140 and $180 for 10mg, 20mg and 30mg.

Both are studied for tissue repair but act through different mechanisms: BPC-157 is a gastric-juice-derived pentadecapeptide investigated for angiogenesis and nitric-oxide signaling, while TB-500 is thymosin beta-4, which works through actin binding and cell migration. (The name TB-500 is used both for the full 43-residue protein, which is what our lot contains, and for its synthetic Ac-LKKTETQ fragment.)

That complementary action is why they are often researched together in a single blend. Evidence for both is preclinical only.

They raise growth hormone through two different receptors, which is exactly why they are studied together.

CJC-1295 is a GHRH analogue acting at the GHRH receptor on the pituitary, increasing the amplitude of the growth hormone pulse; Ipamorelin (CAS 170851-70-4) is a ghrelin-receptor (GHS-R1a) agonist that triggers the pulse itself and, in Raun et al. (1998), did so without meaningfully raising ACTH, cortisol or prolactin. Because the two pathways are complementary rather than duplicative, preclinical models pair them to study a combined effect neither produces alone. We stock Ipamorelin 10mg at $74.99 and the pre-blended CJC-1295 + Ipamorelin 10mg vial at $79.

Yes — Ipamorelin alone is a single ghrelin-receptor agonist, while the blend combines it with the GHRH analog CJC-1295 so two GH pathways are engaged at once.

Preclinical studies pair them because a GHRH-analog plus a secretagogue can produce a greater growth-hormone response than either compound on its own. Supplied for research use only.

BPC-157's evidence is almost entirely preclinical — extensive rodent and in-vitro studies on tissue repair, but no large, published human clinical trials to date.

That places it in a lower evidence tier than clinically validated peptides such as semaglutide or tirzepatide. We rank every compound honestly by evidence level so researchers can weigh them accurately.

Our research peptide vials range from $44.99 to $180 CAD, and shipping is free Canada-wide on every order with no minimum, so the listed price is the delivered price before tax.

At the low end, Semaglutide 5mg is $44.99 and GHK-Cu 50mg is $49; in the middle, BPC-157 10mg and MOTS-C 10mg are $59.99 each, Semaglutide 10mg is $69.99, and Tirzepatide 10mg and Ipamorelin 10mg are $74.99; at the top, Retatrutide runs $90 for 10mg, $140 for 20mg and $180 for 30mg. Larger vials cost less per milligram, and an automatic volume discount begins at three items. Every price includes published lot figures you can check before you order.

You can order all three directly from ThePeptide.ca, each supplied as a lyophilized research vial with published lot figures and free tracked shipping from British Columbia with no minimum.

Retatrutide comes in 10mg at $90, 20mg at $140 and 30mg at $180; Tirzepatide in 10mg at $74.99; Semaglutide in 5mg at $44.99 and 10mg at $69.99. Every lot is verified by HPLC-UV for purity and mass spectrometry for identity — the current Retatrutide 10mg lot reta10-0626-03 at 99.8%, the Tirzepatide lot TIRZ10-0626-01 at 99.65%. All three are supplied strictly as laboratory research material and none is approved by Health Canada.

Because a domestic parcel never crosses a border: no CBSA inspection, no import duties, no brokerage fees and no seizure risk, with delivery in 2–8 business days to major centres, and up to 14 for remote and northern addresses, rather than the two-plus weeks common on overseas orders.

You also get a Canadian point of contact and certificates from Canadian laboratories — Testides in Toronto, VialTests and SideChain Analytics in Mississauga re-test lots that Janoshik Analytical has already assayed. Be clear about what this does and does not mean, though: the compounds themselves are synthesized overseas, as essentially all research peptides are, and Health Canada's position on their regulatory status applies regardless of where you buy them. What is domestic is the logistics, the support and the testing.

Two things.

First, independent lab testing on every lot — each batch is assayed by Janoshik Analytical before release and is then sent for our own confirmatory testing, to Testides in Toronto, to VialTests or to SideChain Analytics in Mississauga, and each lot's figures go up as they clear. Thirteen of our nineteen published lots have completed both steps so far; on the remaining six our confirmation is still in progress and the Janoshik result stands in the meantime, labelled as such. Second, the measured numbers, not a badge — every lot's test figures are published on our Lab Results page under its own lot number: purity by HPLC, mass-spec identity, measured content, method, laboratory and report date, open to anyone with no login, including the figures that are not flattering. We do not host the laboratories' certificate documents; the eight Testides-confirmed lots carry a report number you can check yourself at testides.com/verify, the three VialTests-confirmed lots carry one you can check at vialtests.com/verify, the SideChain-confirmed lot carries its own report reference, and the batch and purity are printed on the vial.

Yes — email info@thepeptide.ca with the compounds, vial sizes and quantities you need and we will send a written quote, usually within 24 hours on business days.

Below wholesale volumes the automatic volume discount already applies at checkout with no code: 10% off at three or more items, 15% at five or more, 20% at ten or more. For institutional buyers we can arrange purchase-order and invoicing terms, and where stock allows we will consolidate an order onto a single verified lot, which matters when a study needs one lot number across all of its material. Free tracked shipping applies at every quantity.

Yes — both are in stock now.

Alongside Retatrutide 10mg ($90, $9.00/mg) we stock Retatrutide 20mg ($140, $7.00/mg) and Retatrutide 30mg ($180, $6.00/mg), our lowest per-milligram price in the range. Each larger vial has its lot figures published: lot CS-re20-0710 at 99.643% and lot CS-re30-0718 at 99.751%, both assayed by Janoshik Analytical on a blind test — the lab was given three candidate compounds and not told which the sample was, and identified retatrutide from its own analysis. Our own Testides confirmation on both lots is still pending, as it is on the eight other lots still awaiting confirmation on our lab results page. All orders ship free and tracked Canada-wide with no minimum.

The mg figure on the label is the mass of lyophilized (freeze-dried) peptide sealed in the vial — total peptide content, not a concentration.

Semaglutide comes in 5mg and 10mg vials, Retatrutide in 10mg, 20mg and 30mg, Tirzepatide, BPC-157, MOTS-C and Ipamorelin in 10mg, GHK-Cu in 50mg, and the pre-blended vials in 10mg made up of 5mg of each component. The certificate for each lot reports the measured net content against that label figure, which is how you confirm a vial is not short-filled — lot reta10-0626-03, for example, assayed at 13.41 mg against a 10 mg label.

No. Every product on this site is supplied strictly as laboratory research material — not for human consumption, not for veterinary use, and not for diagnostic, cosmetic or therapeutic application.

None of these compounds is approved by Health Canada for any of those purposes. Health Canada's public advisory of 9 April 2026 addresses this directly and states that labelling a product "for research use only" does not make it legal or exempt it from regulatory requirements; we do not pretend otherwise. We make no therapeutic claims, we publish no human-use guidance of any kind anywhere on this site, and we do not provide it on request.

Yes — you must be of legal age in your province or territory, which is 18 in Alberta, Manitoba, Ontario, Prince Edward Island, Quebec and Saskatchewan, and 19 in British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, the Northwest Territories, Nunavut and Yukon.

By completing checkout you confirm that you meet that threshold and that you are acquiring the material for lawful laboratory research purposes only. We may decline or cancel any order at our discretion. These compounds are not supplied for human or veterinary use, and Health Canada treats peptides of this kind as generally regulated as prescription drugs.

Not in the sense that phrase is usually meant.

Health Canada's 9 April 2026 advisory is explicit that peptides of this kind are generally regulated as prescription drugs, and that unauthorized drug products are illegal in Canada to sell, advertise or import. Labelling a product "for research use only" is not an exemption from that framework. We supply these compounds strictly as laboratory research material — not for human or veterinary use — and buyers are responsible for lawful, compliant handling under the Food and Drugs Act.

We cannot advise on personal use, and you should not read the absence of a prescription step at checkout as a statement that these compounds are unregulated.

Health Canada treats peptides of this kind as generally regulated as prescription drugs, and unauthorized drug products are illegal to sell or import; "research use only" labelling is not an exemption. Our vials are supplied strictly as laboratory research material to buyers using them for lawful research purposes, never for human or veterinary use.

Every batch is independently tested by Janoshik Analytical before release and is then sent for our own confirmatory HPLC purity and LC-MS/MS identity testing, at Testides in Toronto, VialTests or SideChain Analytics in Mississauga — thirteen of our nineteen published lots have cleared both steps so far, and on the remaining six that confirmation is still in progress.

Every lot's figures are published per batch as they clear, so you can verify what you buy rather than take our word for it. We are Canadian-based with free tracked shipping Canada-wide on every order and no minimum, dispatched within 48 hours from British Columbia in discreet, unbranded packaging.

The core difference is verification depth and transparency: every batch is assayed by Janoshik Analytical and then sent for our own confirmatory testing at Testides in Toronto, VialTests or SideChain Analytics in Mississauga, and we publish each lot's measured figures under its own lot number as they clear — purity, content, method, laboratory and date — instead of a single generic report.

Combined with domestic dispatch within 48 hours and free tracked Canada-wide shipping with no minimum, it is built so researchers can confirm the measured purity of any lot for themselves.

The company is Canadian; the chemistry is not, and we do not blur the two.

ThePeptide.ca is Canadian-owned and operated from New Westminster, British Columbia, and every order is picked, packed and dispatched from there with free tracked shipping Canada-wide. The compounds themselves are synthesized overseas, as essentially all research peptides are, because research-scale peptide synthesis is concentrated in a small number of specialist facilities. Under the Competition Bureau's origin rules, a country-of-origin claim of that kind would require most direct production costs and the last substantial transformation to have happened here; neither did, so we do not make one. What is Canadian is the ownership, the support, the domestic dispatch and the Toronto and Mississauga laboratories that re-test our lots.

The compounds themselves are synthesized overseas, as virtually all research peptides are; ThePeptide.ca is a Canadian-owned company based in New Westminster, British Columbia, and every order ships domestically from there.

We deliberately make no manufacturing-origin claim, because we could not support one. What we can support is measurement: every lot is independently assayed and its figures published under its lot number, reporting purity by HPLC-UV, identity by mass spectrometry, and net peptide content in milligrams. Janoshik Analytical, Testides in Toronto, VialTests and SideChain Analytics in Mississauga are the four laboratories named on those results. We would rather show a researcher the data than a flag.